Search research articles
Contact Us
Filters
Showing results (111-120 of 181) with videos related to
Page
of 19
Sort By:
Investigational New Drugs
|
April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
The Oncologist
|
March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials
Ryan W Huey, Goldy C George, Penny Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors
Alexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Journal of Clinical Pharmacology
|
December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Scientific Reports
|
May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
Shuyang Yao, Funda Meric-Bernstam, David Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 2025
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma
Shubham Pant, Joon Oh Park, Wu-Chou Su, et al.
JCO Precision Oncology
|
February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors
Morten Lapin, Helen J Huang, Sharmeen Chagani, et al.
Investigational New Drugs
|
October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Plos One
|
February 28, 2015
Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells
Dongfeng Qu, Jeremy Johnson, Parthasarathy Chandrakesan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
Shubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 181) with videos related to
Sort By:
Page
of 19
Investigational New Drugs
|
April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
The Oncologist
|
March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials
Ryan W Huey, Goldy C George, Penny Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors
Alexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Journal of Clinical Pharmacology
|
December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Scientific Reports
|
May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
Shuyang Yao, Funda Meric-Bernstam, David Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 2025
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma
Shubham Pant, Joon Oh Park, Wu-Chou Su, et al.
JCO Precision Oncology
|
February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors
Morten Lapin, Helen J Huang, Sharmeen Chagani, et al.
Investigational New Drugs
|
October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Plos One
|
February 28, 2015
Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells
Dongfeng Qu, Jeremy Johnson, Parthasarathy Chandrakesan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
Shubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Page
of 19